Clinical Report: Aspirin’s Cancer Promise Questioned

Overview

Revise to specify that CRC incidence does not significantly reduce in the first 15 years and clarify the mortality increase timeframe.

Background

Colorectal cancer is a major global health concern, ranking as the third most commonly diagnosed cancer and the second leading cause of cancer-related deaths. The potential role of aspirin in reducing CRC incidence has been debated for decades, yet recent evidence suggests that its benefits may be limited and overshadowed by risks. Understanding the implications of aspirin use for CRC prevention is crucial for guiding clinical practice and patient management.

Data Highlights

No significant reduction in CRC incidence was observed with aspirin use over 5 to 15 years, with potential increased mortality in the first 5 to 10 years and a confirmed increase in serious bleeding risks.

Key Findings

• Aspirin showed little to no difference in CRC incidence compared to control groups at 5 to 15 years of follow-up.
• Increased CRC mortality was associated with aspirin use in older adults during the first 5 to 10 years.
• Serious extracranial hemorrhage risk increased from approximately 8 to 12 per 1,000 patients with aspirin use.
• Higher doses of aspirin correlated with greater bleeding risks compared to low-dose regimens.
• Long-term benefits of aspirin for CRC prevention remain uncertain and may be delayed beyond 15 years.

Clinical Implications

Current evidence does not support the routine use of aspirin for primary prevention of CRC in the general population. Clinicians should weigh the potential risks, particularly serious bleeding, against the uncertain benefits of aspirin in older adults and consider individualized approaches based on cardiovascular risk.

Conclusion

The findings from this review underscore the need for cautious interpretation of aspirin's role in CRC prevention, emphasizing the importance of balancing potential harms with uncertain benefits.

References

1. Cochrane Database of Systematic Reviews, 2026 -- Aspirin’s Cancer Promise Questioned
2. The New Gastroenterologist — Aspirin at Low Doses Decreases Recurrence of Colorectal Cancer
3. ADA News — Potential Protective Effects of Aspirin Against Colorectal Cancer
4. The ASCO Post — Important Caveats to Consider Concerning Low-Dose Daily Aspirin for the Primary Prevention of Colorectal Cancer
5. The ASCO Post — Expect Questions on Use of Low-Dose Aspirin to Help Prevent Colorectal Cancer
6. New USPSTF Recommendation on Aspirin in CVD: No For Primary Prevention, Yes For Secondary Prevention
7. Cancer Incidence and Mortality With Aspirin in Older Adults: Follow-Up of the ASPREE Trial
8. Recommendations | Colorectal cancer | Guidance | NICE